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Abstract
Background: The sex hormone-binding globulin (SHBG) is a carrier protein that modulates the
bio-availability of serum sex steroid hormones, which may be involved in ovarian cancer. We
evaluated whether common genetic variation in SHBG and its 3' neighbor ATP1B2, in linkage
disequilibrium, is associated with the risk of epithelial ovarian cancer.
Methods: The study population included 264 women with ovarian carcinoma and 625 controls
participating in a population-based case-control study in Poland. Five common single nucleotide
polymorphisms (SNPs) in SHGB and five in ATP1B2 were selected to capture most common
variation in this region.
Results: None of the SNPs evaluated was significantly associated with ovarian cancer risk, including
the putative functional SNPs SHBG D356N (rs6259) and -67G>A 5'UTR (rs1799941). However,
our data were consistent with a decreased ovarian cancer risk associated with the variant alleles
for these two SNPs, which have been previously associated with increased circulating levels of
SHBG.
Conclusion:  These data do not support a substantial association between common genetic
variation in SHBG and ovarian cancer risk.
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Background
Hormonal stimulation of ovarian epithelial cells has been
proposed as a mechanism for carcinogenesis of the ova-
ries [1]. The evidence for sex steroid hormones playing a
role in ovarian cancer is primarily indirect, based on ani-
mal and in vitro studies, as well epidemiological observa-
tions [1], while the relationship between circulating levels
of sex steroids and ovarian cancer risk has not been clearly
demonstrated [2,3].
The sex steroid hormone-binding globulin (SHBG) gene
regulates the action of sex steroid hormones by modulat-
ing their bioavailability to target tissues such as the ovaries
[4]. The SHBG gene is located on the short arm of chro-
mosome 17. A non-synonymous SNP in exon 8 results in
an amino acid substitution of asparagine for aspartic acid
(D356N, rs6259) in the SHBG protein, and the asparagine
(N) allele of SHBG has been associated with elevated cir-
culating levels of SHBG in post-menopausal women [5-7].
An additional SNP in the 5' untranslated region (UTR) of
SHBG has also been associated with elevated SHBG levels
[6]. These data suggest that common variation in SHBG
has functional relevance and thus, could affect the risk of
hormonally-related cancers.
We performed a detailed assessment of common genetic
variation in SHBG  and evaluated the possibility of an
association with ovarian cancer risk in the Polish Ovarian
Cancer Study. We included SNPs in the SHBG 3' flanking
gene ATPase, Na+/K+ transporting beta 2 polypeptide
(ATP1B2) because of the observation of linkage disequi-
librium (LD) that extends across SHBG and ATP1B2 based
on a re-sequencing study [8]. The enzyme encoded by
ATP1B2 is involved in establishing and maintaining the
electrochemical gradients of Na and K ions across the
plasma membrane. Inclusion of neighboring genes in
studies of relationships between disease and common
genetic variation is of interest because they could affect
the regulation of the protein of interest.
Methods
Study population
The Polish Ovarian Cancer Study is a population-based
case-control study of ovarian cancer conducted among
female residents of Warsaw and Lodz (Poland), 20–74
years of age. Eligible cases consisted of all women newly
diagnosed with histologically confirmed ovarian carci-
noma or a borderline tumor identified during the study
period (June 2001 – December 2003). We identified a
total of 437 eligible cases. Most (76%) cases were idendit-
fied through a rapid ascertainment system in participating
hospitals, and the remaining cases (24%) missed by this
system were identified through cancer registries. Control
women were randomly selected within matching strata
from complete population lists (PESEL database) of War-
saw and Lodz residents from 2001 to 2004, and were fre-
quency matched to cases on age (5-year groups) and study
site (Warsaw and Lodz). Women who reported a previous
diagnosis of ovarian cancer or bilateral oopherectomy
were excluded as controls. Of the eligible cases and con-
trols, 78% and 69%, respectively, agreed to participate in
the study. The main reasons for non-participation among
eligible subjects included: refusal to participate (11%
cases and 24% controls); unable to locate (3% cases and
7% controls), and deceased (7% cases and <0.1% con-
trols). This resulted in 341 cases and 1994 controls partic-
ipating in the main study.
All participants underwent a personal interview regarding
known or suspected ovarian cancer risk factors. The
median time from diagnosis to interview was 2.4 months,
ranging from 5 days to one year. Of the interviewed
women, 315 (92%) cases and 1911 (96%) controls pro-
vided a blood or buccal cell sample for DNA extraction;
however, eight of these cases were excluded because of
limited amounts of DNA or quality control problems.
This report is limited to carcinomas; therefore 22 cases
with borderline tumors and 21 cases with non-epithelial
tumors were further excluded from the analyses, leaving
264 cases (241 with blood and 23 with buccal cell DNA).
For costs-efficiency, we randomly selected a sample of 625
controls with blood DNA to approximate a 1:2 case:con-
trol ratio. Thus, final analyses included a total of 264 cases
and 625 controls. All study participants were of Polish
Caucasian origin. The study protocol was reviewed and
approved by local and NCI Institutional Review Boards
(IRBs). All participants provided written informed con-
sent.
Genotyping
Single nucleotide polymorphism (SNP) selection was
based on a re-sequence analysis of TP53 and its neighbor-
ing genes, which include SHBG and ATP1B2, performed
in 94 healthy Norwegian women and 102 individuals in
the SNP500 Cancer panel [8]. SNPs in SHBG and ATP1B2
with a minor allele frequency >0.05 were identified dur-
ing a re-sequence analysis of all exons, evolutionarily con-
served regions and promoter regions and were genotyped
in the Polish Ovarian Cancer Study. Genotype analyses
were performed at the Core Genotyping Facility (CGF) of
the Division of Cancer Epidemiology and Genetics, NCI
for 5 SNPs in SHBG (rs1799941, -67G>A 5'UTR; rs6257,
IVS1-17T>C; rs6259, Ex8+6G>A (D356N); rs727428,
1121 bp 3' of STP T>C; and rs1641544 31959 bp 3' of STP
T>C); and 5 SNPs in ATP1B2  (rs1641536, -8852T>C;
rs1641535 -8703T>C; rs1624085 x2G>C; rs1641512,
Ex7+414G>A).
Description and methods for each genotype assay can be
found at [9,10]. Duplicated DNA pairs from 70 subjects inBMC Cancer 2007, 7:60 http://www.biomedcentral.com/1471-2407/7/60
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the study showed 100% concordance for all assays. Com-
pletion was ≥ 98% for all assays. We observed no signifi-
cant departures from Hardy-Weinberg equilibrium in the
control population.
Statistical Analyses
As an estimate of relative risk, odds ratios (OR) and their
95% confidence intervals (CI) were derived from uncon-
ditional logistic regression models that included dummy
variables for the matching factors, i.e. age in 5 year catego-
ries and study site (Lodz or Warsaw). The association
between genotypes and ovarian cancer risk was tested
using a trend test, except for rare alleles in which hetero-
zygous and homozygous variants were combined. We
evaluated heterogeneity in the ORs observed for the geno-
type analysis on the basis of age, number of lifetime ovu-
latory cycles and family history of ovarian and/or breast
cancer in first degree relatives, by introducing interaction
terms in logistic regression models. Number of lifetime
ovulatory cycles was used as a measure of a women's
potential ovulatory life, and was calculated as previously
described [11].
Pairwise linkage disequilibrium (LD) was estimated
between SNPs based on D'and r2 values using Haploview
[12]. Block structure was determined using genotype data
from the control population, and the solid spline of LD
option (D' threshold > 0.80). Haplotype frequencies
within each block, ORs and their 95%CIs were estimated
using HaploStats (version 1.2.1) [13,14]. A global score
statistic, adjusted for the matching factors age (in 5 year
categories) and study site (Lodz or Warsaw), was used to
evaluate the overall difference in haplotype frequencies
between cases and controls.
Results
The cases included in this analysis were diagnosed at a
mean (SD) age of 56.2 (11.0) years. Tumor characteristics
include: 45% had serous carcinomas, 62% had distal
metastases, and 52% had tumors with poor grade of dif-
ferentiation (Table 1). As expected, serous, mixed and
unclassified tumors were frequently poorly differentiated
(69%, 75% and 90%, respectively), with a lower percent-
age of poorly differentiated tumors among endometriod
(36%) and mucinous (19%) carcinomas. Compared to
control women, cases were more frequently nulliparous
or had fewer full-term births, had a larger number of life-
time ovulatory cycles, and more frequently reported a first
degree family history of a first-degree relative with ovarian
or breast cancer (Table 1). Cases were also less likely to
have used oral contraceptives. These differences were con-
sistent with known or suspected risk factors for ovarian
cancer [15].
A map of LD in the control population across the 10 SNPs
evaluated is shown in Additional file 1. Three of the eval-
uated polymorphisms (rs1641537, rs1641536 and
rs1641535 in ATP1B1) showed strong correlations (pair-
wise r2 > 0.98) and, to avoid redundancy, only data for
one of the correlated SNPs are shown in Table 2. Geno-
types with the variant alleles for the putative functional
SNPs in SHBG, D356N (rs6259) and -67G>A 5'UTR
(rs1799941), were less common among cases than con-
trols; however, differences were not statistically significant
(Table 2). These two SNPs showed low correlation (r2 =
0.03). Evaluation of joint effects suggested that subjects
with genotypes carrying variant alleles for both SNPs
could be at particularly low risk (OR (95%CI) for subjects
with the rs6259 AG/GG and rs1799941 AG/GG genotypes
(9 cases and 36 controls) was 0.47 (0.22–1.02), p = 0.06,
compared to common homozygous for both SNPs (122
cases and 237 controls). However, the interaction
between these two SNPs was not statistically significant (p
= 0.15). None of the other SNPs evaluated were signifi-
cantly associated with ovarian cancer risk. Associations
with the SNPs evaluated in this report were not signifi-
cantly modified by age, menopausal status, first degree
family history of breast or ovarian cancer, or number of
lifetime ovulatory cycles (data not shown). Associations
were also not significantly modified by histological type
or stage at diagnosis (data not shown).
Haplotype analyses including all non-redundant SNPs
(i.e excluding rs1641536 and rs1641535 in ATP1B1)
showed nine haplotypes with frequencies >0.01, with no
significant overall association with ovarian cancer risk
(global p = 0.42; Table 3). Only one haplotype, present in
5% of cases and controls, carried the D356N (rs6259)
SNP and showed no significant association with risk com-
pared to the haplotype carrying the common alleles for
each of the SNPs evaluated (ATACCCCG). Although none
of the individual haplotypes were significantly associated
with risk, there was a borderline significant association for
the most common haplotype (frequent in 35% of con-
trols) which carried a variant for a SNP in the 5'UTR of
SHBG (rs1799941). Data were consistent with an inverse
association for women carrying this haplotype (GTAC-
CCCG) compared to the ATACCCCG haplotype (OR
95%CI = 0.77 (0.58–1.01); Table 3).
Discussion
This detailed evaluation of common genetic variation in
SHBG including its neighboring gene ATP1B2, does not
support a substantial association between common vari-
ants and ovarian cancer risk. However, the possibility of
weak to modest associations could not be excluded.
The asparagine (N) allele of SHBG D356N and the variant
allele of the -67G>A 5'UTR SNP in SHBG have been asso-BMC Cancer 2007, 7:60 http://www.biomedcentral.com/1471-2407/7/60
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Table 1: Personal and tumor characteristics of 264 ovarian cancer cases and 625 controls in the Polish Ovarian Cancer Study.
Cases* N = 264 Controls* N = 625 P**
Study site, N %
Warsaw 177 67% 423 68% 0.85
Lodz 87 33% 202 32%
Age, mean SD in years 56.3 10.8 56.1 10.8 0.83
No. of full-term births, N %
Nulliparous 50 19% 79 13% <0.0001
1 101 38% 176 28%
2 94 36% 273 44%
≥ 31 9 7 % 9 7 1 6 %
Number of ovulatory 
cycles, mean SD
410.9 71.1 398.1 81.3 0.03
Use of oral contraceptive, N %
Never 245 94% 556 90% 0.08
Ever 16 6% 60 10%
Currently having menstrual periods, N %
No 182 71% 401 66% 0.40
Yes 75 29% 203 34%
Unclear 7 3% 20 3%
Use of oral hormone replacement therapy among post-menopausal women
Never 146 81% 325 82%
Ever 35 19% 70 18% 0.15
Family history of breast or ovarian cancer in first-degree relatives, N %
No 210 80% 553 88% 0.001
Breast cancer only 26 10% 24 4%
Ovarian cancer 
only
26 10% 40 6%
Both 2 1% 8 1%
Tumor Characteristics
Histology, N (%)
Serous 118 45%
Mucinous 26 10%
Endometrioid 58 22%
Clear cell 14 5%
Mixed 18 7%
Others or 
unclassified
30 11%
Stage, N % distant 110 62%
Not staged or 
missing
86
Grade of differentiation, N %
Well 21 13%
Moderate 59 35%
Poor 88 52%
Missing 96
* Differences between the total number of cases and controls and frequencies shown in the table are due to missing data.
** P values for categorical variables are based on chi squared tests, and on t-tests for continuous variables.BMC Cancer 2007, 7:60 http://www.biomedcentral.com/1471-2407/7/60
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ciated with elevated SHBG circulating levels [5-7]. There-
fore, these SNP could result in a reduced bioavailability of
estrogen or other sex-steroids, and a reduction in risk of
hormonally-related cancers. Although the frequency of
the genotypes with the variant alleles for these two SNPs
was lower for cases than controls, differences were not sta-
tistically significant. A pentanucleotide (TAAAA)n repeat
polymorphism, not measured in our study, has been
found to be linked to the D356N SNP in Caucasian pop-
ulations, as well as associated with elevated levels of
SHBG [7]. Therefore, it is possible that functional changes
not directly measured in our study might be related to
risk. Given the lack of data from previous studies of ovar-
ian cancer on the common variation in SHBG, further
studies are needed to clarify potential relationships.
The main limitation of this study was limited power to
detect weak to modest associations. Specifically, the study
size provided 80% power to detect ORs of 1.5 or 0.7 for
MAFs ranging from 0.10 to 0.50, assuming an additive
mode of inheritance; and MAFs ranging from 0.20 to 0.35,
assuming a dominant inheritance. However, the power to
detect associations for MAF outside these ranges, recessive
associations, or gene-gene/gene-environment interactions
was low. Therefore, such associations could have missed
in our study.
Table 2: Risk of epithelial ovarian cancer and polymorphisms in SHBG and its 3' neighbor ATP1B2, among 264 ovarian cancer cases and 
625 controls in the Polish Ovarian Cancer Study*
Gene SNP Cases Controls OR** 95% CI P-trend
SHBG
rs1799941 AA 144 278 1.00
-67G>A AG 118 287 0.79 0.59 – 1.07
5'UTR GG 23 57 0.79 0.46 – 1.33 0.14
rs6257 TT 242 520 1.00
IVS1-17T>C TC 41 91 0.97 0.65 – 1.44
CC 2 2 2.13 0.29 – 15.3 0.75
rs6259 AA 254 547 1.00
Ex8+6G>A AG 30 72 0.89 0.57 – 1.40
D356N GG 1 4 0.51 0.06 – 4.65 0.72
rs727428 CC 119 264 1.00
1121 bp 3' of STP 
T>C
CT 121 278 0.96 0.71 – 1.30
TT 45 81 1.25 0.81 – 1.91 0.48
rs1641544 CC 261 580 1.00
31959 bp 3' of STP 
T>C
CT 22 38 1.34 0.77 – 2.33 0.30
TT 1 0
ATP1B2
rs1641537 *** CC 215 486 1.00
-9115T>C CT 66 125 1.21 0.86 – 1.71
TT 3 8 0.90 0.23 – 3.46 0.36
rs1624085 CC 116 246 1.00
Ex2G>C CG 120 292 0.86 0.64 – 1.18
GG 49 84 1.25 0.82 – 1.90 0.60
rs1641512 GG 193 401 1.00
Ex7+414G>A GA 80 195 0.86 0.63 – 1.17
AA 12 27 0.94 0.46 – 1.90 0.42
* Differences between the total number of cases and controls and frequencies shown in the table are due to missing genotype data.
** Adjusted for age and city.
*** Highly correlated with ATP1B1 rs1641536 (18852T>C) and rs1641535 (-8703T>c), r2 > 0.98, not shown in table to avoid redundancy.BMC Cancer 2007, 7:60 http://www.biomedcentral.com/1471-2407/7/60
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This population-based study has among the highest par-
ticipation rate attained in population-based studies with
collection of biological specimens. However, collection of
DNA samples inevitably reduces overall participation
rates and could introduce selection bias. This bias is
unlikely to be of relevance in this report because the eval-
uated SNPs are unlikely to be related to potential selection
factors. Further, the observed allele frequency for the
SHBG D356N was similar to previously published studies
among Caucasians [6], and the distribution of ovarian
cancer risk factors in cases and controls was consistent
with known or suspected risk factors for ovarian cancer
[15].
Conclusion
This report of a detailed assessment of genetic variation in
SHBG including its neighboring gene ATP1B2, does not
support a substantial association between common varia-
tion in this region and ovarian cancer risk. However, weak
or modest associations could not be excluded, particularly
a reduced risk of ovarian cancer hypothesized for the func-
tional SNPs D356N and -67G>A 5'UTR. Therefore, further
evaluation in larger study populations is warranted.
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Supplementary Figure 1: Patterns of linkage disequilibrium across the 
SHBG and its 3' neighbor gene ATP1B2. The figure provided shows Pat-
terns of linkage disequilibrium across the SHBG and its 3' neighbor gene 
ATP1B2.
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Table 3: Risk of epithelial ovarian cancer and SHBG-ATP1B2 extended haploptypes, among 264 ovarian cancer cases and 625 controls in 
the Polish Ovarian Cancer Study
Haplotype frequency OR 95%CI P
Haplotypes* Cases Controls
A T A C C C C G 0.26 0.20 1.00 (reference**)
G . . . . . . . 0.32 0.35 0.77 0.58 – 1.01 0.06
. . . . . . G A 0.01 0.02 0.43 0.14 – 1.33 0.14
. . . T . . G . 0.12 0.11 0.89 0.60 – 1.33 0.58
. . . T . T G A 0.09 0.09 0.83 0.56 – 1.23 0.36
. . . T T T G A 0.04 0.03 1.22 0.70 – 2.12 0.49
. . G T . . G A 0.05 0.05 0.81 0.50 – 1.30 0.38
. C . T . . G . 0.07 0.07 0.81 0.53 – 1.25 0.34
G . . . . . G . 0.01 0.02 0.51 0.17 – 1.58 0.24
Global p = 0.42
* Polymorphic bases in 5' to 3' order: SHBG (rs1799941, rs6257, rs6259, rs727428, rs1641544); ATP1B2 (rs16441537, rs1624085, rs1641512). Two 
ATP1B2 SNPs (rs1641536 and rs1641535) highly correlated (r2 > 0.98) with rs1641537 are not included in the analyses.
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